Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2018/5893514 http://scihub22266oqcxt.onion/10.1155/2018/5893514 C5901476!5901476!29808090     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Endocrinol 2018 ; 2018 (ä): ä Nephropedia Template TP {{tp|p=29808090|t=2018. Role of the Wnt/?-Catenin Pathway in Renal Osteodystrophy |pdf=|usr=}}{{29808090}} gab.com Text Role of the Wnt/ -Catenin Pathway in Renal Osteodystrophy JO: Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29808090 #FOAvip Vascular calcification and bone fragility are common and interrelated health problems that affect chronic kidney disease (CKD) patients. Bone fragility, which leads to higher risk of fracture and mortality, arises from the abnormal bone remodeling and mineralization that are seen in chronic kidney disease. Recently, sclerostin and Dickkopf-related protein 1 were suggested to play a significant role in CKD-related bone disease as they are known inhibitors of the Wnt pathway, thus preventing bone formation. This review focuses on new knowledge about the Wnt pathway in bone, how its function is affected by chronic kidney disease and how this affects bone structure. Expression of components and inhibitors of the Wnt pathway has been shown to be affected by the loss of kidney function, and a better understanding of the bone effects of Wnt pathway inhibitors could allow the development of new therapies to prevent bone fragility in this population. Twit Text FOAVip Role of the Wnt/ -Catenin Pathway in Renal Osteodystrophy ????Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29808090 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29808090 #FOAvip English Wikipedia <ref>{{Cite pmid|29808090}}</ref> Role of the Wnt/?-Catenin Pathway in Renal Osteodystrophy #MMPMID29808090 Bisson SK; Ung RV; Mac-Way F Int J Endocrinol 2018[]; 2018 (ä): ä PMID29808090show ga Vascular calcification and bone fragility are common and interrelated health problems that affect chronic kidney disease (CKD) patients. Bone fragility, which leads to higher risk of fracture and mortality, arises from the abnormal bone remodeling and mineralization that are seen in chronic kidney disease. Recently, sclerostin and Dickkopf-related protein 1 were suggested to play a significant role in CKD-related bone disease as they are known inhibitors of the Wnt pathway, thus preventing bone formation. This review focuses on new knowledge about the Wnt pathway in bone, how its function is affected by chronic kidney disease and how this affects bone structure. Expression of components and inhibitors of the Wnt pathway has been shown to be affected by the loss of kidney function, and a better understanding of the bone effects of Wnt pathway inhibitors could allow the development of new therapies to prevent bone fragility in this population. äRole of the Wnt/?-Catenin Pathway in Renal Osteodystrophy (epmc).pdf DeepDyve Pubget Overpricing